10x Genomics Statistics
Total Valuation
10x Genomics has a market cap or net worth of $3.17 billion. The enterprise value is $2.77 billion.
Important Dates
The next estimated earnings date is Thursday, May 7, 2026, after market close.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
10x Genomics has 127.75 million shares outstanding. The number of shares has increased by 3.57% in one year.
| Current Share Class | 117.67M |
| Shares Outstanding | 127.75M |
| Shares Change (YoY) | +3.57% |
| Shares Change (QoQ) | +1.26% |
| Owned by Insiders (%) | 8.22% |
| Owned by Institutions (%) | 99.02% |
| Float | 115.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.00 |
| Forward PS | 5.18 |
| PB Ratio | 3.78 |
| P/TBV Ratio | 4.40 |
| P/FCF Ratio | 24.69 |
| P/OCF Ratio | 23.62 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.32 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 21.32 |
Financial Position
The company has a current ratio of 4.46, with a Debt / Equity ratio of 0.11.
| Current Ratio | 4.46 |
| Quick Ratio | 3.95 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.65 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -5.78% and return on invested capital (ROIC) is -7.49%.
| Return on Equity (ROE) | -5.78% |
| Return on Assets (ROA) | -6.40% |
| Return on Invested Capital (ROIC) | -7.49% |
| Return on Capital Employed (ROCE) | -11.29% |
| Weighted Average Cost of Capital (WACC) | 15.79% |
| Revenue Per Employee | $545,690 |
| Profits Per Employee | -$36,964 |
| Employee Count | 1,178 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 2.85 |
Taxes
In the past 12 months, 10x Genomics has paid $3.64 million in taxes.
| Income Tax | 3.64M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +208.86% in the last 52 weeks. The beta is 2.17, so 10x Genomics's price volatility has been higher than the market average.
| Beta (5Y) | 2.17 |
| 52-Week Price Change | +208.86% |
| 50-Day Moving Average | 20.23 |
| 200-Day Moving Average | 16.25 |
| Relative Strength Index (RSI) | 70.38 |
| Average Volume (20 Days) | 2,180,599 |
Short Selling Information
The latest short interest is 16.02 million, so 12.54% of the outstanding shares have been sold short.
| Short Interest | 16.02M |
| Short Previous Month | 15.81M |
| Short % of Shares Out | 12.54% |
| Short % of Float | 13.89% |
| Short Ratio (days to cover) | 6.50 |
Income Statement
In the last 12 months, 10x Genomics had revenue of $642.82 million and -$43.54 million in losses. Loss per share was -$0.35.
| Revenue | 642.82M |
| Gross Profit | 444.38M |
| Operating Income | -100.29M |
| Pretax Income | -39.91M |
| Net Income | -43.54M |
| EBITDA | -64.09M |
| EBIT | -100.29M |
| Loss Per Share | -$0.35 |
Full Income StatementBalance Sheet
The company has $523.41 million in cash and $84.36 million in debt, with a net cash position of $439.05 million or $3.44 per share.
| Cash & Cash Equivalents | 523.41M |
| Total Debt | 84.36M |
| Net Cash | 439.05M |
| Net Cash Per Share | $3.44 |
| Equity (Book Value) | 796.33M |
| Book Value Per Share | 6.24 |
| Working Capital | 531.00M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $136.05 million and capital expenditures -$5.94 million, giving a free cash flow of $130.12 million.
| Operating Cash Flow | 136.05M |
| Capital Expenditures | -5.94M |
| Depreciation & Amortization | 36.20M |
| Net Borrowing | n/a |
| Free Cash Flow | 130.12M |
| FCF Per Share | $1.02 |
Full Cash Flow StatementMargins
Gross margin is 69.13%, with operating and profit margins of -15.60% and -6.77%.
| Gross Margin | 69.13% |
| Operating Margin | -15.60% |
| Pretax Margin | -6.21% |
| Profit Margin | -6.77% |
| EBITDA Margin | -9.97% |
| EBIT Margin | -15.60% |
| FCF Margin | 20.24% |
Dividends & Yields
10x Genomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.57% |
| Shareholder Yield | -3.57% |
| Earnings Yield | -1.36% |
| FCF Yield | 4.05% |
Analyst Forecast
The average price target for 10x Genomics is $17.61, which is -29.08% lower than the current price. The consensus rating is "Hold".
| Price Target | $17.61 |
| Price Target Difference | -29.08% |
| Analyst Consensus | Hold |
| Analyst Count | 15 |
| Revenue Growth Forecast (5Y) | 5.73% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
10x Genomics has an Altman Z-Score of 2.67 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.67 |
| Piotroski F-Score | 4 |
